Furthermore, CD44-Doxil exhibited higher doxorubicin concentrations within tumor cells as well as excellent antitumor efficacy and improved therapeutic effect compared with Doxil-treated C-26 colon cancer mice. This evidence concerns the gene CD44 and colonic neoplasm.